[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561317":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":41,"responsibleParty":58,"collaborators":26,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":26,"enrollmentInfo":70,"targetDuration":26,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":43,"whyStopped":26,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"University of Florida","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ABCD-GENE-guided de-escalation","EXPERIMENTAL","ABCD-GENE ≥10: prasugrel 10 mg qd or ticagrelor 90 mg od monotherapy. ABCD-GENE \\\u003C10: Aspirin 81 mg qd and clopidogrel 75 mg qd.",[13],"Drug: Prasugrel\u002FTicagrelor monotherapy or aspirin plus clopidogrel",{"label":15,"type":16,"description":17,"interventionNames":18},"Unguided de-escalation","ACTIVE_COMPARATOR","Aspirin 81 mg qd and clopidogrel 75 mg qd.",[19],"Drug: Aspirin plus clopidogrel",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Prasugrel\u002FTicagrelor monotherapy or aspirin plus clopidogrel","After at least 30 days of DAPT \\[with aspirin 81-mg qd and a potent P2Y12 inhibitor (prasugrel 10 mg qd or ticagrelor 90-mg BID)\\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients with an ABCD-GENE 10 or more will continue prasugrel 10 mg qd\u002Fticagrelor 90 mg BID and drop aspirin; and patients with an ABCD-GENE less than10 will switch from prasugrel\u002Fticagrelor-based DAPT to aspirin 81 mg qd plus clopidogrel 75 mg qd.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Aspirin plus clopidogrel","After at least 30 days of DAPT \\[with aspirin 81 mg qd and a potent P2Y12 inhibitor (prasugrel 10 mg qd or ticagrelor 90 mg BID)\\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will switch from prasugrel\u002Fticagrelor-based DAPT to aspirin 81 mg qd plus clopidogrel 75 mg qd, irrespective of ABCD-GENE score.",[15],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Luis Ortega, MD, PhD","CONTACT","904-244 2060","Luis.Ortega@jax.ufl.edu",{"name":38,"role":34,"phone":39,"phoneExt":26,"email":40},"Andrea Burton, MPH, CCRP","904-244-5617","Andrea.Burton@jax.ufl.edu",[42],{"facility":5,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Jacksonville","Florida","32209","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-81.65565,30.33218,{"lat":53,"lon":52},[56],{"name":33,"role":34,"phone":57,"phoneExt":26,"email":36},"904-244-2060",{"type":59,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100561317","phase-4-the-switching-antiplatelet-9-swap-9-study-100561317",false,"NCT06588595","The Switching Antiplatelet-9 (SWAP-9) Study","Comparison of ABCD-GENE Score-Guided Versus Unguided DAPT De-Escalation: A Prospective Randomized Pharmacodynamic Study in Patients Undergoing PCI The Switching Antiplatelet-9 (SWAP-9) Study","SWAP-9","Inclusion Criteria:\n\n1. Patients who have undergone PCI and are on maintenance treatment with DAPT, composed of low-dose aspirin (81mg qd) with either prasugrel (10 mg qd) or ticagrelor (90 mg bid). In particular, patients who underwent PCI in the setting of an acute coronary syndrome will be eligible for randomization after ≥90 days post-PCI, while patients who underwent PCI in the setting of a chronic coronary syndrome ≥30 days post-PCI.\n2. Age ≥18 years\n3. Provide written informed consent.\n\nExclusion Criteria:\n\n1. Prior history of stent thrombosis\n2. PCI within 30 days\n3. On treatment with any oral anticoagulant (vitamin K antagonists, dabigatran, rivaroxaban, apixaban, edoxaban) or chronic low-molecular-weight heparin (at venous thrombosis treatment, not for prophylaxis)\n4. Hemodynamic instability\n5. Hypersensitivity to clopidogrel\n6. Known platelet count less than 80x10\\^6\u002FmL\n7. Known hemoglobin less than 9 g\u002FdL\n8. Pregnant and breastfeeding women \\[women of childbearing age must use reliable birth control (i.e., oral contraceptives) while participating in the study\\].","ALL","18 Years",{"count":71,"type":72},90,"ESTIMATED","INTERVENTIONAL",[75],"PHASE4","The purpose of this study is to compare the pharmacodynamic effects of ABCD-GENE guided vs. unguided de-escalation strategies among patients on dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI).",[78],"Coronary Arterial Disease (CAD)",[80,81,82,83,84],"ABCD-GENE score","Dual antiplatelet therapy (DAPT)","Pharmacodynamic (PD) study","Percutaneous coronary intervention (PCI)","P2Y12 receptor inhibitor","2026-02-24",{"date":87,"type":88},"2026-02-25","ACTUAL",{"date":90,"type":88},"2024-11-01",{"date":92,"type":72},"2027-02-28",{"name":5,"class":6},1]